

James O'donnell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7328619/publications.pdf>

Version: 2024-02-01

144
papers

6,414
citations

81900

39
h-index

74163

75
g-index

144
all docs

144
docs citations

144
times ranked

8250
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. <i>Lancet Rheumatology</i> , The, 2020, 2, e437-e445.	3.9	652
2	ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?. <i>Transfusion</i> , 2006, 46, 1836-1844.	1.6	343
3	COVID19 coagulopathy in Caucasian patients. <i>British Journal of Haematology</i> , 2020, 189, 1044-1049.	2.5	307
4	The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology. <i>British Journal of Haematology</i> , 2014, 167, 453-465.	2.5	297
5	ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. <i>Blood Advances</i> , 2021, 5, 280-300.	5.2	246
6	Elevated factor VIII levels and risk of venous thrombosis. <i>British Journal of Haematology</i> , 2012, 157, 653-663.	2.5	236
7	Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. <i>Blood</i> , 2005, 105, 1085-1093.	1.4	217
8	Persistent endotheliopathy in the pathogenesis of long COVID syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2546-2553.	3.8	208
9	Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. <i>British Journal of Haematology</i> , 2000, 110, 454-460.	2.5	192
10	Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1064-1070.	3.8	142
11	Amount of HAntigen Expressed on Circulating von Willebrand Factor Is Modified by ABO Blood Group Genotype and Is a Major Determinant of Plasma von Willebrand Factor Antigen Levels. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 335-341.	2.4	125
12	Endothelial cells orchestrate COVID-19 coagulopathy. <i>Lancet Haematology</i> , the, 2020, 7, e553-e555.	4.6	122
13	von Willebrand factor propeptide in malaria: evidence of acute endothelial cell activation. <i>British Journal of Haematology</i> , 2006, 133, 562-569.	2.5	116
14	Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. <i>Blood</i> , 2009, 114, 1658-1665.	1.4	113
15	Rapid activation of endothelial cells enables Plasmodium falciparum adhesion to platelet-decorated von Willebrand factor strings. <i>Blood</i> , 2010, 115, 1472-1474.	1.4	112
16	Severe Plasmodium falciparum Malaria Is Associated with Circulating Ultra-Large von Willebrand Multimers and ADAMTS13 Inhibition. <i>PLoS Pathogens</i> , 2009, 5, e1000349.	4.7	105
17	Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. <i>Blood</i> , 2005, 106, 1988-1991.	1.4	99
18	Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. <i>Blood</i> , 2017, 130, 2344-2353.	1.4	98

#	ARTICLE	IF	CITATIONS
19	Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation. <i>British Journal of Haematology</i> , 2021, 192, 714-719.	2.5	92
20	Expression of terminal α 2-6-linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13. <i>Blood</i> , 2010, 115, 2666-2673.	1.4	79
21	Significant gynecological bleeding in women with low von Willebrand factor levels. <i>Blood Advances</i> , 2018, 2, 1784-1791.	5.2	79
22	The relationship between ABO blood group, von Willebrand factor, and primary hemostasis. <i>Blood</i> , 2020, 136, 2864-2874.	1.4	75
23	More on COVID-19 coagulopathy in Caucasian patients. <i>British Journal of Haematology</i> , 2020, 189, 1060-1061.	2.5	73
24	Platelet von Willebrand factor α 2C structure, function and biological importance. <i>British Journal of Haematology</i> , 2010, 148, 834-843.	2.5	69
25	Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis. <i>Blood</i> , 2013, 122, 4107-4110.	1.4	65
26	Elucidating the role of carbohydrate determinants in regulating hemostasis: insights and opportunities. <i>Blood</i> , 2013, 121, 3801-3810.	1.4	63
27	ADAMTS13 regulation of VWF multimer distribution in severe COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1914-1921.	3.8	58
28	ABO Blood Group Phenotypes and Plasmodium falciparum Malaria: Unlocking a Pivotal Mechanism. <i>Advances in Parasitology</i> , 2007, 65, 1-50.	3.2	56
29	Emerging roles for hemostatic dysfunction in malaria pathogenesis. <i>Blood</i> , 2016, 127, 2281-2288.	1.4	54
30	A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance. <i>Blood</i> , 2018, 131, 911-916.	1.4	54
31	Neutrophils in COVID-19: Not Innocent Bystanders. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	52
32	Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. <i>British Journal of Haematology</i> , 2001, 115, 687-691.	2.5	51
33	von Willebrand factor clearance α 2C biological mechanisms and clinical significance. <i>British Journal of Haematology</i> , 2018, 183, 185-195.	2.5	51
34	The endothelial cell protein C receptor: cell surface conductor of cytoprotective coagulation factor signaling. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 717-726.	5.4	49
35	A Tyr346 \rightarrow Cys substitution in the interdomain acidic region1 of factor VIII in an individual with factor VIII:C assay discrepancy. <i>British Journal of Haematology</i> , 2002, 118, 589-594.	2.5	46
36	Advances in understanding the molecular mechanisms that maintain normal haemostasis. <i>British Journal of Haematology</i> , 2019, 186, 24-36.	2.5	46

#	ARTICLE	IF	CITATIONS
37	Genotype at the Secretor blood group locus is a determinant of plasma von Willebrand factor level. <i>British Journal of Haematology</i> , 2002, 116, 350-356.	2.5	45
38	Vaccine-induced immune thrombotic thrombocytopenia (VITT) – a novel clinical pathological entity with heterogeneous clinical presentations. <i>British Journal of Haematology</i> , 2021, 195, 76-84.	2.5	42
39	A novel role for von Willebrand factor in the pathogenesis of experimental cerebral malaria. <i>Blood</i> , 2016, 127, 1192-1201.	1.4	41
40	Role of the Thrombelastograph as an adjunctive test in thrombophilia screening. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 207-211.	1.0	38
41	Dissociation of Activated Protein C Functions by Elimination of Protein S Cofactor Enhancement. <i>Journal of Biological Chemistry</i> , 2008, 283, 30531-30539.	3.4	38
42	Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis. <i>Intensive Care Medicine</i> , 2021, 47, 899-902.	8.2	38
43	How I treat low von Willebrand factor levels. <i>Blood</i> , 2019, 133, 795-804.	1.4	36
44	Blood group alters platelet binding kinetics to von Willebrand factor and consequently platelet function. <i>Blood</i> , 2019, 133, 1371-1377.	1.4	36
45	More on – Association between ABO blood groups and risk of SARS-CoV-2 pneumonia™. <i>British Journal of Haematology</i> , 2020, 190, 27-28.	2.5	35
46	Emerging Roles for von Willebrand Factor in Cancer Cell Biology. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 159-166.	2.7	34
47	Efficacy and safety of once daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 689-692.	1.0	32
48	Clinical utility gene card for: Haemophilia A. <i>European Journal of Human Genetics</i> , 2011, 19, 1-3.	2.8	32
49	Increased galactose expression and enhanced clearance in patients with low von Willebrand factor. <i>Blood</i> , 2019, 133, 1585-1596.	1.4	32
50	An international survey to inform priorities for new guidelines on von Willebrand disease. <i>Haemophilia</i> , 2020, 26, 106-116.	2.1	32
51	N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance. <i>Blood</i> , 2016, 128, 1959-1968.	1.4	31
52	Advances in understanding the molecular mechanisms of venous thrombosis. <i>British Journal of Haematology</i> , 2019, 186, 13-23.	2.5	31
53	Telehealth for delivery of haemophilia comprehensive care during the COVID-19 pandemic. <i>Haemophilia</i> , 2020, 26, 984-990.	2.1	31
54	Activated Protein C N-Linked Glycans Modulate Cytoprotective Signaling Function on Endothelial Cells. <i>Journal of Biological Chemistry</i> , 2011, 286, 1323-1330.	3.4	30

#	ARTICLE	IF	CITATIONS
55	von Willebrand factor sialylationâ€”A critical regulator of biological function. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1018-1029.	3.8	30
56	Plasmin Cleaves Von Willebrand Factor at K1491-R1492 in the A1â€”A2 Linker Region in a Shear- and Glycan-Dependent Manner In Vitro. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 845-855.	2.4	29
57	Biological mechanisms underlying interâ€”individual variation in factor VIII clearance in haemophilia. <i>Haemophilia</i> , 2020, 26, 575-583.	2.1	29
58	Concentration-dependent roles for heparin in modifying lipopolysaccharide-induced activation of mononuclear cells in whole blood. <i>Thrombosis and Haemostasis</i> , 2008, 99, 570-575.	3.4	28
59	von Willebrand factor arginine 1205 substitution results in accelerated macrophageâ€”dependent clearance in vivo. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 821-826.	3.8	28
60	New treatment approaches to von Willebrand disease. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 683-689.	2.5	27
61	N-linked glycan truncation causes enhanced clearance of plasma-derived von Willebrand factor. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2446-2457.	3.8	27
62	New developments in von Willebrand disease. <i>British Journal of Haematology</i> , 2020, 191, 329-339.	2.5	27
63	Does antithrombotic therapy improve survival in cancer patients?. <i>Blood Reviews</i> , 2009, 23, 129-135.	5.7	26
64	Parasite histones are toxic to brain endothelium and link blood barrier breakdown and thrombosis in cerebral malaria. <i>Blood Advances</i> , 2020, 4, 2851-2864.	5.2	25
65	Low-density lipoprotein receptor-related protein polymorphisms in patients with elevated factor VIII coagulant activity and venous thrombosis. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 465-468.	1.0	24
66	Platelet Factor 4 Impairs the Anticoagulant Activity of Activated Protein C. <i>Journal of Biological Chemistry</i> , 2009, 284, 5869-5875.	3.4	23
67	A microfluidic anti-Factor Xa assay device for point of care monitoring of anticoagulation therapy. <i>Analyst</i> , 2013, 138, 4769.	3.5	23
68	Galectin-1 and Galectin-3 Constitute Novel-Binding Partners for Factor VIII. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 855-863.	2.4	23
69	Review: Primary thromboprophylaxis in the palliative care setting: a qualitative systematic review. <i>Palliative Medicine</i> , 2010, 24, 386-395.	3.1	22
70	Activated factor X signaling via protease-activated receptor 2 suppresses pro-inflammatory cytokine production from lipopolysaccharide-stimulated myeloid cells. <i>Haematologica</i> , 2014, 99, 185-193.	3.5	22
71	Low VWF: insights into pathogenesis, diagnosis, and clinical management. <i>Blood Advances</i> , 2020, 4, 3191-3199.	5.2	22
72	Activated protein C β -glycoform promotes enhanced noncanonical PAR1 proteolysis and superior resistance to ischemic injury. <i>Blood</i> , 2015, 126, 915-919.	1.4	20

#	ARTICLE	IF	CITATIONS
73	Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12531.	2.3	18
74	How I treat bleeding disorder of unknown cause. <i>Blood</i> , 2021, 138, 1795-1804.	1.4	18
75	Breast cancer cells mediate endothelial cell activation, promoting von Willebrand factor release, tumor adhesion, and transendothelial migration. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2350-2365.	3.8	18
76	von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis. <i>Blood Advances</i> , 2022, 6, 62-71.	5.2	17
77	Therapeutic implications of ongoing alveolar viral replication in COVID-19. <i>Lancet Rheumatology</i> , The, 2022, 4, e135-e144.	3.9	17
78	Nanoparticle Biomolecular Corona-Based Enrichment of Plasma Glycoproteins for N-Glycan Profiling and Application in Biomarker Discovery. <i>ACS Nano</i> , 2022, 16, 5463-5475.	14.6	17
79	Development of a fluorescent anti-factor Xa assay to monitor unfractionated and low molecular weight heparins. <i>Talanta</i> , 2010, 81, 1725-1730.	5.5	16
80	Targeting von Willebrand Factor-Mediated Inflammation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1590-1591.	2.4	16
81	Measurement of the viscoelastic properties of blood plasma clot formation in response to tissue factor concentration-dependent activation. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 6581-6588.	3.7	14
82	Perioperative management of patients with von Willebrand disease. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 604-609.	2.5	14
83	Pulmonary intravascular coagulopathy in COVID-19 pneumonia – Authors' reply. <i>Lancet Rheumatology</i> , The, 2020, 2, e460-e461.	3.9	14
84	The protein C β -loop substitution Asn21le is associated with reduced protein C anticoagulant activity. <i>British Journal of Haematology</i> , 2009, 144, 946-953.	2.5	13
85	Engineering activated protein C to maximize therapeutic efficacy. <i>Biochemical Society Transactions</i> , 2015, 43, 691-695.	3.4	12
86	X-linked moyamoya syndrome associated with severe haemophilia A. <i>Haemophilia</i> , 2016, 22, e51-e54.	2.1	12
87	Platelets in malaria pathogenesis. <i>Blood</i> , 2018, 132, 1222-1224.	1.4	12
88	Acquired protein s deficiency in thrombotic thrombocytopenic purpura patients receiving solvent/detergent plasma exchange. <i>British Journal of Haematology</i> , 2003, 122, 518-519.	2.5	11
89	Illustrated State-of-the-Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 431-497.	2.3	11
90	Title is missing!. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 283-287.	1.0	10

#	ARTICLE	IF	CITATIONS
91	The Immunoregulatory Activities of Activated Protein C in Inflammatory Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 167-175.	2.7	10
92	The Biological Significance of von Willebrand Factor O-Linked Glycosylation. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 855-861.	2.7	10
93	Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort. <i>Haemophilia</i> , 2021, 27, 618-625.	2.1	9
94	Current practice and registration patterns among United Kingdom Haemophilia Centre Doctors™ Organisation centers for patients with unclassified bleeding disorders. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2738-2743.	3.8	9
95	Investigating the clearance of VWF A-domains using site-directed PEGylation and novel N-linked glycosylation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1278-1290.	3.8	8
96	Sialylation on O-linked glycans protects von Willebrand factor from macrophage galactose lectin-mediated clearance. <i>Haematologica</i> , 2022, 107, 668-679.	3.5	8
97	Dissociation of ABH antigen expression from von Willebrand factor synthesis in endothelial cell lines. <i>British Journal of Haematology</i> , 2003, 121, 928-931.	2.5	7
98	A role for intravenous immunoglobulin in the treatment of Acquired Von Willebrand Syndrome associated with IgM gammopathy. <i>Haemophilia</i> , 2018, 24, e22-e25.	2.1	7
99	Apolipoprotein A-I enhances activated protein C cytoprotective activity. <i>Blood Advances</i> , 2020, 4, 2404-2408.	5.2	7
100	Management of elective procedures in low von Willebrand factor patients in the LoVIC study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 701-710.	3.8	7
101	Examining international practices in the management of pregnant women with von Willebrand disease. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 82-91.	3.8	7
102	Single centre, real-world experience of perioperative rFIXFc use in adult patients with haemophilia B undergoing major and minor surgery. <i>Haemophilia</i> , 2021, 27, e690-e697.	2.1	7
103	Beta-adrenergic receptor polymorphisms in patients with elevated factor VIII levels with venous thrombosis. <i>British Journal of Haematology</i> , 2003, 123, 139-141.	2.5	6
104	Comparative study of Factor Xa fluorogenic substrates and their influence on the quantification of LMWHs. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 399, 691-700.	3.7	6
105	Bleeding assessment tools in the diagnosis of VWD in adults and children: a systematic review and meta-analysis of test accuracy. <i>Blood Advances</i> , 2021, 5, 5023-5031.	5.2	6
106	Practical treatment guidance for cancer-associated thrombosis – Managing the challenging patient: A consensus statement. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103599.	4.4	6
107	Elevated plasma factor VIII levels in patients with venous thrombosis – Constitutional risk factor or secondary epiphenomenon?. <i>Thrombosis Research</i> , 2012, 129, 105-106.	1.7	5
108	Age-related factor IX correction in symptomatic female carriers with haemophilia B Leyden. <i>Haemophilia</i> , 2015, 21, e498-e500.	2.1	5

#	ARTICLE	IF	CITATIONS
109	Out of Sight, out of Mind? An Audit Which Proposes a Follow-Up and Management Pathway for Inferior Vena Cava Filters. <i>Thrombosis</i> , 2016, 2016, 1-3.	1.4	5
110	Validation of Risk-Adapted Venous Thromboembolism Prediction in Multiple Myeloma Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 3536.	2.4	5
111	Persistent endotheliopathy in the pathogenesis of long COVID syndrome –Reply to comment from von Meijenfeldt et al.. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 270-271.	3.8	5
112	von Willebrand disease: proposing definitions for future research. <i>Blood Advances</i> , 2021, 5, 565-569.	5.2	5
113	The von Willebrand factor – ADAMTS-13 axis in malaria. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12641.	2.3	5
114	Longitudinal bleeding assessment in von willebrand disease utilising an interim bleeding score. <i>Journal of Thrombosis and Haemostasis</i> , 0, , .	3.8	5
115	Comparison of a fluorogenic anti-FXa assay with a central laboratory chromogenic anti-FXa assay for measuring LMWH activity in patient plasmas. <i>Thrombosis Research</i> , 2011, 128, e125-e129.	1.7	4
116	Management of combined factor V and factor VIII deficiency in pregnancy. <i>Journal of Obstetrics and Gynaecology</i> , 2019, 39, 271-272.	0.9	4
117	Recombinant factor IX-Fc fusion protein in severe hemophilia B: Patient-reported outcomes and health-related quality of life. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12602.	2.3	4
118	Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays. <i>Thrombosis Research</i> , 2011, 128, e166-e170.	1.7	3
119	Microbiome influences von Willebrand factor. <i>Blood</i> , 2017, 130, 393-395.	1.4	3
120	Expresser phenotype determines ABO(H) blood group antigen loading on platelets and von Willebrand factor. <i>Scientific Reports</i> , 2020, 10, 18366.	3.3	3
121	Heterogeneity in Bleeding Tendency and Arthropathy Development in Individuals with Hemophilia. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 183-191.	2.7	3
122	Antithrombin inhibition using nanobodies to correct bleeding in hemophilia. <i>EMBO Molecular Medicine</i> , 2020, 12, e12143.	6.9	3
123	Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis. <i>Blood Advances</i> , 2022, 6, 3735-3745.	5.2	3
124	Hemostatic and protein C pathway dysfunction in the pathogenesis of experimental cerebral malaria. <i>Haematologica</i> , 2022, 107, 1950-1954.	3.5	3
125	Perspective: The Case for Acute Large Vessel Ischemic Stroke in COVID-19 Originating Within Thrombosed Pulmonary Venules. <i>Stroke</i> , 2022, 53, 2411-2419.	2.0	3
126	Enhanced VWF clearance in low VWF pathogenesis: limitations of the VWFpp/VWF:Ag ratio and clinical significance. <i>Blood Advances</i> , 2023, 7, 302-308.	5.2	3

#	ARTICLE	IF	CITATIONS
127	von Willebrand disease and von Willebrand factor. Haemophilia, 2022, 28, 11-17.	2.1	3
128	Pharmacotherapy of hyperhomocysteinaemia in patients with thrombophilia. Expert Opinion on Pharmacotherapy, 2002, 3, 1591-1598.	1.8	2
129	Clinical utility gene card for: haemophilia B. European Journal of Human Genetics, 2012, 20, 3-3.	2.8	2
130	Oral Rivaroxaban for Pulmonary Embolism. New England Journal of Medicine, 2012, 366, 2525-2527.	27.0	2
131	von Willebrand factor promotes wound healing. Blood, 2019, 133, 2553-2555.	1.4	2
132	von Willebrand Factor Antigen, von Willebrand Factor Propeptide, and ADAMTS13 in Carotid Stenosis and Their Relationship with Cerebral Microemboli. Thrombosis and Haemostasis, 2021, 121, 086-097.	3.4	2
133	Toward Personalized Treatment for Patients with Low von Willebrand Factor and Quantitative von Willebrand Disease. Seminars in Thrombosis and Hemostasis, 2021, 47, 192-200.	2.7	2
134	Illustrated State of the Art Capsules of the ISTH 2021 Congress. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12532.	2.3	2
135	Clinical utility gene card for: von Willebrand disease. European Journal of Human Genetics, 2011, 19, 615-615.	2.8	1
136	Quantification of unfractionated heparin in human plasma and whole blood by means of novel fluorogenic anti-FXa assays. Journal of Pharmaceutical and Biomedical Analysis, 2011, 56, 992-997.	2.8	1
137	Effects of four commercially available factor Xa proteins on the fluorogenic anti-factor Xa assay when monitoring unfractionated heparin. Blood Coagulation and Fibrinolysis, 2012, 23, 98-103.	1.0	1
138	Recurrent lower limb venous thrombosis associated with a congenitally absent infrarenal inferior vena cava. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 57-57.	0.5	1
139	Rapid Whole Blood Clot Retraction Assay on Quartz Crystal Microbalance. , 2021, 5, 1-4.		1
140	Correcting dominant negative von Willebrand disease. Journal of Thrombosis and Haemostasis, 2021, 19, 55-57.	3.8	1
141	Younger Age at Diagnosis Is Associated with an Increased Risk of Venous Thromboembolism in Multiple Myeloma. Blood, 2018, 132, 1223-1223.	1.4	1
142	Antithrombin Nagasaki (Ser 116 to Pro): a rare antithrombin variant with abnormal heparin binding presenting during pregnancy. Blood Coagulation and Fibrinolysis, 2006, 17, 217-220.	1.0	0
143	A novel microfluidic anti-factor Xa assay device for monitoring anticoagulant therapy at the point-of-care. Proceedings of SPIE, 2013, , .	0.8	0
144	Novel therapies for hemophilia A - the role of the von Willebrand factor chaperone. Journal of Thrombosis and Haemostasis, 2019, 17, 426-428.	3.8	0